| Popis: |
Yu Zhang,1,* Jie Luo,2,* Rongquan He,3 Wenting Huang,1 Zuyun Li,1 Ping Li,1 Yiwu Dang,1 Gang Chen,1 Shikang Li4 1Department of Pathology, 2Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, 3Center for Genomic and Personalized Medicine, Guangxi Medical University, 4Department of Thoracic and Cardiovascular Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China *These authors contributed equally to this work Background: Decoy receptor 3 (DcR3) has been reported to be involved in different cancers. However, few related researches have been accomplished on the role of DcR3 in lung cancer. Objective: To explore the expression level and clinicopathological implication of DcR3 protein in lung cancer tissues. Materials and methods: Immunohistochemistry was used to examine DcR3 protein expression in lung cancer (n=365) and normal lung tissues (n=26). The relationships between DcR3 expression and clinical parameters were further investigated. Furthermore, the diagnostic and clinicopathological value of DcR3 mRNA was analyzed based on The Cancer Genome Atlas database in lung cancer patients. Results: Compared to normal lung tissues, DcR3 expression was significantly higher in lung cancer (P=0.007) tissues, including small-cell lung cancer (P=0.001) and non-small-cell lung cancer (P=0.008). In addition, DcR3 expression was related to tumor-node-metastasis (TNM) stage (P |
